PMID- 22085302
OWN - NLM
STAT- MEDLINE
DCOM- 20120312
LR  - 20151119
IS  - 1521-0758 (Electronic)
IS  - 0191-3123 (Linking)
VI  - 35
IP  - 6
DP  - 2011 Dec
TI  - Clinical significance of IEX-1 expression in ovarian carcinoma.
PG  - 260-6
LID - 10.3109/01913123.2011.608916 [doi]
AB  - BACKGROUND: The stress-inducible immediate early response gene X-1 (IEX-1) 
      regulates cell proliferation and apoptosis in a cell type and stimulus-dependent 
      manner. The aim of this study was to investigate IEX-1 expression and its role in 
      apoptosis of ovarian epithelial tumors for potential use in clinical diagnosis 
      and therapy. METHODS: IEX-1 expression was examined in paraffin-embedded 
      specimens from 77 patients with epithelial ovarian tumors using 
      immunohistochemistry. Correlation between IEX-1 expression and other 
      clinicopathological parameters was evaluated. Apoptosis of tumor cells was 
      detected by terminal deoxynucleotide transferase-mediated dUTP nick end labeling 
      (TUNEL). RESULTS: IEX-1 expression was significantly lower in ovarian cancers 
      compared to cystadenomas and borderline tumors (p < .05). The expression was 
      significantly associated with FIGO stage and histological grade (p < .05), but 
      not with age, histological type, or residual tumor (p > .05). A positive 
      correlation was also observed between IEX-1 expression and apoptotic index (p < 
      .01) or survival (p=.005). CONCLUSION: With the development of epithelial ovarian 
      tumors from benign to malignant, IEX-1 expression is decreased, concomitant with 
      a decreased rate of cell apoptosis. Thus, IEX-1 is pro-apoptotic in the 
      development of epithelial ovarian cancer. The pro-apoptotic activity may take 
      part in restraining tumor growth at the early stage of ovarian epithelial cancer, 
      whereas its decreased expression probably contributes to the abnormal survival 
      advantage for malignant cancer. Altered IEX-1 expression can potentially be a new 
      predictor of the malignant transformation and a prognostic indicator for cancer 
      therapy.
FAU - Han, Liping
AU  - Han L
AD  - Department of Obstetrics and Gynaecology, The First Affiliated Hospital, 
      Zhengzhou University, Henan, China. hanlp0825@yahoo.com.cn
FAU - Geng, Lina
AU  - Geng L
FAU - Liu, Xiangrong
AU  - Liu X
FAU - Shi, Huirong
AU  - Shi H
FAU - He, Wei
AU  - He W
FAU - Wu, Mei X
AU  - Wu MX
LA  - eng
PT  - Journal Article
PL  - England
TA  - Ultrastruct Pathol
JT  - Ultrastructural pathology
JID - 8002867
RN  - 0 (Apoptosis Regulatory Proteins)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (IER3 protein, human)
RN  - 0 (Membrane Proteins)
SB  - IM
CIN - Ultrastruct Pathol. 2012 Aug;36(4):285. PMID: 22849530
MH  - Adenocarcinoma/*chemistry/mortality/pathology
MH  - Apoptosis
MH  - Apoptosis Regulatory Proteins/*analysis
MH  - Biomarkers, Tumor/*analysis
MH  - Chi-Square Distribution
MH  - China
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Nick-End Labeling
MH  - Kaplan-Meier Estimate
MH  - Membrane Proteins/*analysis
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Ovarian Neoplasms/*chemistry/mortality/pathology
MH  - Paraffin Embedding
MH  - Proportional Hazards Models
MH  - Risk Assessment
MH  - Risk Factors
MH  - Survival Rate
MH  - Time Factors
EDAT- 2011/11/17 06:00
MHDA- 2012/03/13 06:00
CRDT- 2011/11/17 06:00
PHST- 2011/11/17 06:00 [entrez]
PHST- 2011/11/17 06:00 [pubmed]
PHST- 2012/03/13 06:00 [medline]
AID - 10.3109/01913123.2011.608916 [doi]
PST - ppublish
SO  - Ultrastruct Pathol. 2011 Dec;35(6):260-6. doi: 10.3109/01913123.2011.608916.